ASX:IVXInvion Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Invion Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add 0.0080 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.01Now: A$0.01▼A$0.0150-Day RangeA$0.01MA: A$0.01▼A$0.0152-Week RangeA$0.01Now: A$0.01▼A$0.03Volume471,000 shsAverage VolumeN/AMarket Capitalization$44.00 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Invion Limited, a clinical-stage drug development company, develops treatments for chronic inflammatory and autoimmune diseases in Australia and the United States. Its drug candidates in phase II clinical trials include INV102, a beta blocker to treat chronic inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease; and INV104, a leukotriene receptor antagonist that reduces inflammation, constriction of the airways, and build-up of mucus in the lungs. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers. Invion Limited is based in East Kew, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Invion. Previous Next 2.6 Community Rank Outperform VotesInvion has received 19 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInvion has received 18 “underperform” votes. (Add your “underperform” vote.)Community SentimentInvion has received 51.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Invion and other stocks. Vote “Outperform” if you believe IVX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IVX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInvion does not currently pay a dividend.Dividend GrowthInvion does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invion insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Invion is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invion is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvion has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolASX:IVX Previous Symbol CUSIPN/A CIKN/A Webwww.inviongroup.com Phone61 3 9081 6005Debt Debt-to-Equity Ratio0.30 Current Ratio1.37 Quick Ratio1.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.57 million Price / Sales9.64 Cash FlowA$0.00 per share Price / Cash Flow15.00 Book ValueA$0.00 per share Price / Book8.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares5,500,610,048Market Cap$44.00 million Next Earnings DateN/A OptionableNot Optionable Receive IVX News and Ratings via Email Sign-up to receive the latest news and ratings for IVX and its competitors with MarketBeat's FREE daily newsletter. Invion (ASX:IVX) Frequently Asked Questions How has Invion's stock been impacted by COVID-19 (Coronavirus)? Invion's stock was trading at A$0.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IVX stock has increased by 14.3% and is now trading at A$0.01. View which stocks have been most impacted by Coronavirus. Has Invion been receiving favorable news coverage? Press coverage about IVX stock has been trending negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Invion earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Invion. Who are some of Invion's key competitors? Some companies that are related to Invion include ESSA Pharma (EPI), Probiotec (PBP), Green Organic Dutchman (TGOD), Shield Therapeutics (STX), WeedMD (WMD), cbdMD (YCBD), Althea Group (AGH), Supreme Cannabis (FIRE), Delta 9 Cannabis (NINE), Flowr (FLWR), Venture Life Group (VLG), Biosyent (RX), Acerus Pharmaceuticals (ASP), MMJ Group (MMJ) and Auscann Group (AC8). View all competitors. What other stocks do shareholders of Invion own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invion investors own include Walt Disney (DIS), Centurylink (CTL), Carlisle Companies (CSL), Cape Lambert Resources (CFE), Camtek (CAMT), Boston Properties (BXP), BioSpecifics Technologies (BSTC), BJ's Restaurants (BJRI), Banco Bradesco (BBD) and Aggreko (AGK). Who are Invion's key executives? Invion's management team includes the following people: Dr. Gregory Royce Collier, MD, CEO & Exec. Director (Age 60)Ms. Melanie Farris, Head of Operations & Company Sec.Dr. Mitchell Glass, Exec. VP of R&D, Chief Medical Officer and Exec. Director (Age 66)Mr. Tom Coogan, ConsultantDr. Dean Naylor, Head of Intellectual Property Devel. What is Invion's stock symbol? Invion trades on the ASX under the ticker symbol "IVX." What is Invion's stock price today? One share of IVX stock can currently be purchased for approximately A$0.01. How big of a company is Invion? Invion has a market capitalization of $44.00 million and generates $4.57 million in revenue each year. What is Invion's official website? The official website for Invion is www.inviongroup.com. How can I contact Invion? The company can be reached via phone at 61 3 9081 6005. This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
